Subscribe
Rapid Reactions

HARMONi-2: Phase 3 Study of Ivonescimab vs Pembrolizumab in 1L Treatment for Patients with PD-L1-Positive Advanced NSCLC

Rapid Reactions
WCLC 2024 HER2-Mutated NSCLC
Videos

In this video, Beth Sandy, MSN, CRNP, FAPO, discusses ivonescimab, a bispecific antibody targeting PD-1 and VEGF that produced a tolerable safety profile and clinically significant improvement in efficacy compared with pembrolizumab.

Image of Beth Sandy, MSN, CRNP, FAPO

Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA

Sponsored by

Boehringer Ingelheim Logo

Related Items

Longer-Term Follow-Up of Amivantamab + Lazertinib vs Osimertinib From the MARIPOSA Study
Videos
Rapid Reactions
Zongertinib, a Novel HER2-Specific Tyrosine Kinase Inhibitor for HER2-Positive Solid Tumors with Brain Metastases
Videos
Rapid Reactions
Targeting HER2-Mutated NSCLC With Zongertinib
Videos
Rapid Reactions
Updated Data From ASCO of Beamion LUNG-1, a Phase 1a/1b Trial of Zongertinib in Patients With HER2 Aberration-Positive Solid Tumors
Videos
Rapid Reactions
Ongoing Phase 3 Randomized Trial, Beamion LUNG-2, of Zongertinib Versus Standard of Care in Patients With Advanced NSCLC Harboring HER2 TKD Mutations
Videos
Rapid Reactions
Data From ASCO 2024: Exposure-Response Analysis of Trastuzumab Deruxtecan to Inform Dosing in Patients With HER2-Mutated NSCLC
Videos
Rapid Reactions
Final Results of DESTINY-Lung02 from ASCO 2024: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC
Videos
Rapid Reactions
Real-World Community Practice Experience With Luspatercept Following Erythropoiesis-Stimulating Agent Failure in Patients With Lower-Risk Myelodysplastic Syndromes
Videos
Rapid Reactions
Evaluating Oral Azacitidine for the Treatment of Low- or Intermediate-Risk Myelodysplastic Syndromes
Videos
Rapid Reactions
IMerge Clinical Data in Patients With Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents
Videos
Rapid Reactions

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?